Astellas Pharma Inc. (TYO:4503)
2,000.00
0.00 (0.00%)
At close: Dec 5, 2025
Astellas Pharma Employees
Astellas Pharma had 13,643 employees as of March 31, 2025. The number of employees decreased by 1,111 or -7.53% compared to the previous year.
Employees
13,643
Change (1Y)
-1,111
Growth (1Y)
-7.53%
Revenue / Employee
147.09M JPY
Profits / Employee
9.15M JPY
Market Cap
3,582.43B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Chugai Pharmaceutical | 5,026 |
| HOYA Corporation | 37,909 |
| Takeda Pharmaceutical Company | 47,455 |
| Daiichi Sankyo Company | 19,765 |
| Otsuka Holdings | 35,338 |
| Shionogi & | 4,955 |
| Olympus | 29,297 |
| M3, Inc. | 15,360 |
Astellas Pharma News
- 1 day ago - Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting - PRNewsWire
- 5 days ago - EMA Validates Review Of Astellas' PADCEV And KEYTRUDA Combination In Bladder Cancer - Nasdaq
- 14 days ago - Pfizer : FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Nasdaq
- 4 weeks ago - Q2 2026 Astellas Pharma Inc Earnings Presentation Transcript - GuruFocus
- 4 weeks ago - Full Year 2025 Astellas Pharma Inc Earnings Presentation Transcript - GuruFocus
- 6 weeks ago - Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA) - PRNewsWire
- 6 weeks ago - Astellas Pharma Announces Encouraging Data From OPTION-VMS Phase IV Study - Nasdaq
- 6 weeks ago - Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study - PRNewsWire